Drug intelligence / Profile preview

ENNO-001

Development stage: Preclinical
Lead developer: Ennovate Pharma
Modality: Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

ENNO-001 is a next-generation biologic being developed by Ennovate Pharma for the treatment of autoimmune and inflammatory diseases. It is designed as either a monovalent or bifunctional/bispecific molecule that modulates signaling through the interleukin-1 (IL-1) receptor family. By targeting this pathway, ENNO-001 aims to address the underlying inflammatory processes associated with various chronic conditions. The drug is currently in the preclinical lead stage of development.

Targets

IL-1R fam (IL-1 receptor family)

Beyond the preview

Go deeper on ENNO-001.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ENNO-001.

Explore the full profile